Renal fibrosis originates from diverse etiologies, including diabetes, hypertension, glomerulonephritis and prolonged obstruction, which lead to persistent inflammation and altered repair processes that drive fibrogenesis. M2 macrophages, especially those expressing the macrophage mannose receptor (CD206), play a crucial role in driving fibrogenesis.
Scientists from Shenzhen Medical Academy of Research and Translation and the Southern Medical University have synthesized solute carrier family 22 member 12 (SLC22A12; URAT1) inhibitors. They are reported to be useful for the treatment of kidney injury, hyperuricemia and gout.
Researchers from China hypothesized that Takeda G protein-coupled receptor 5 (TGR5), also known as G-protein coupled bile acid receptor 1, could have therapeutic potential in acute kidney injury by inhibiting ferroptosis.
A group at the University of Antwerp has patented ferroptosis inhibitors. They are reported to be useful for the treatment of acute renal failure, sepsis, ischemia-reperfusion injury and more.
Renal ischemia-reperfusion injury (IRI) is a type of acute kidney injury commonly affecting hospitalized patients and associated with poor outcomes, including increased risk of death in severe cases. IRI is caused by a transient reduction in renal blood flow followed by blood reperfusion.
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have defined cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be useful for the treatment of chronic kidney disease, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome as well as kidney and myocardial fibrosis.
Mediar Therapeutics Inc. has announced an oversubscribed $76 million series B financing to support its novel anti-fibrotics through clinical studies. The funding will also be used to advance MTX-439 into phase I for the treatment of chronic kidney disease (CKD)-associated fibrosis.
Huayao Jiyuan (Shenzhen) Pharmaceutical Co. Ltd. has described hypoxia inducible factor-2α (HIF-2α; EPAS1) inhibitors reported to be useful for the treatment of cancer, infections, cardiovascular disorders, anemia, chronic kidney disease, disorders of hematopoiesis, inflammatory disorders and acute respiratory distress syndrome (ARDS).
Renal fibrosis represents a key driver of the pathology of chronic kidney disease (CKD), marked by fibroblast activation, tubular damage and inflammation. Previous work found that cyclic guanosine monophosphate (cGMP) levels are markedly reduced in experimental models of renal fibrosis, but the reasons for this decline are not fully understood.
RSS
